Home/Pipeline/Pridopidine

Pridopidine

Huntington's disease

Phase 3Active

Key Facts

Indication

Huntington's disease

Phase

Phase 3

Status

Active

Company

Prilenia develops sigma‑1 receptor agonists, led by Phase 3 pridopidine for HD and ALS.

Prilenia develops sigma‑1 receptor agonists, led by Phase 3 pridopidine for HD and ALS.

Prilenia develops sigma‑1 receptor agonists, led by Phase 3 pridopidine for HD and ALS.

Prilenia develops sigma‑1 receptor agonists, led by Phase 3 pridopidine for HD and ALS.

Prilenia develops sigma‑1 receptor agonists, led by Phase 3 pridopidine for HD and ALS.

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
Huntington's Disease Program	Rumi Scientific	Pre-clinical	Active
SOM3355	SOM Biotech	Phase 3	Active
LETI-101	ElevateBio	Preclinical	Active
Somatic Expansion Inhibitor Program	LoQus23 Therapeutics	Preclinical	Active
Preclinical Program	Excision BioTherapeutics	Preclinical	Active
NA-841	Biomed	Phase 2A	Active
T3D-959 (Future)	T3D Therapeutics	Pre-clinical / Research	Active
HD mAb Therapy	HD Immune	Pre-clinical	Active
TT-P34	Teitur Trophics	Pre-clinical	Active
INT41	Vybion	Pre-clinical	Active
Huntington's Program	reMYND	Pre-clinical	Active